» Articles » PMID: 23999969

Novel TRAF1-ALK Fusion Identified by Deep RNA Sequencing of Anaplastic Large Cell Lymphoma

Overview
Date 2013 Sep 4
PMID 23999969
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Chromosomal translocations leading to expression of abnormal fusion proteins play a major role in the pathogenesis of various hematologic malignancies. The recent development of high-throughput, "deep" sequencing has allowed discovery of novel translocations leading to a rapid increase in understanding these diseases. Translocations involving the anaplastic lymphoma kinase (ALK) gene leading to ALK fusion proteins originally were discovered in anaplastic large cell lymphomas (ALCLs). Among ALCLs, NPM1-ALK fusions are most common and lead to nuclear localization of the fusion protein. Here, we present a 50-year-old male with ALCL demonstrating cytoplasmic ALK immunoreactivity only, suggesting the presence of a non-NPM1 fusion partner. We performed deep RNA sequencing of tumor tissue from this patient and identified a novel transcript fusing Exon 6 of TRAF1 to Exon 20 of ALK. The TRAF1-ALK fusion transcript was confirmed at the mRNA level by Sanger sequencing and the fusion protein was visualized by Western blot. The discovery of this TRAF1-ALK fusion expands the diversity of known ALK fusion partners and highlights the power of deep sequencing for fusion transcript discovery. © 2013 Wiley Periodicals, Inc.

Citing Articles

Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.

Sotirov S, Dimitrov I Int J Mol Sci. 2024; 25(9).

PMID: 38732150 PMC: 11084719. DOI: 10.3390/ijms25094934.


Updates in pathobiological aspects of anaplastic large cell lymphoma.

Wu R, Lim M Front Oncol. 2023; 13:1241532.

PMID: 37810974 PMC: 10556522. DOI: 10.3389/fonc.2023.1241532.


How molecular advances may improve the diagnosis and management of PTCL patients.

Drieux F, Lemonnier F, Gaulard P Front Oncol. 2023; 13:1202964.

PMID: 37427095 PMC: 10328093. DOI: 10.3389/fonc.2023.1202964.


Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Zhang X, Chien P, Nam S, Heo C Cancers (Basel). 2022; 14(7).

PMID: 35406421 PMC: 8997054. DOI: 10.3390/cancers14071650.


Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.

Wang Y, He J, Xu M, Xue Q, Zhu C, Liu J Front Oncol. 2022; 12:815654.

PMID: 35211406 PMC: 8862178. DOI: 10.3389/fonc.2022.815654.